Skip to Content
You are currently on the new version of our website. Access the old version .

2,343 Results Found

  • Review
  • Open Access
65 Citations
8,614 Views
18 Pages

Immunomodulatory Roles of PARP-1 and PARP-2: Impact on PARP-Centered Cancer Therapies

  • José Yélamos,
  • Lucia Moreno-Lama,
  • Jaime Jimeno and
  • Syed O. Ali

8 February 2020

Poly(ADP-ribose) polymerase-1 (PARP-1) and PARP-2 are enzymes which post-translationally modify proteins through poly(ADP-ribosyl)ation (PARylation)—the transfer of ADP-ribose chains onto amino acid residues—with a resultant modulation of...

(This article belongs to the Special Issue PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer)
  • Abstract
  • Open Access
1,634 Views
2 Pages

Differences in Durability of PARP Inhibition by PARP Inhibitors in Ovarian Cancer Cells

  • Hannah Louise Smith,
  • Asima Mukhopadhyay,
  • Yvette Drew,
  • Elaine Willmore and
  • Nicola Curtin

Background: PARP inhibitors (PARPi) exploit defects in homologous recombination repair (HRR) to selectively kill tumour cells. Continuous PARP inhibition is required for cytotoxicity. PARPis rucaparib, olaparib, and niraparib have been approved for u...

(This article belongs to the Proceedings of The 1st International Electronic Conference on Cancers: Exploiting Cancer Vulnerability by Targeting the DNA Damage Response)
  • Review
  • Open Access
123 Citations
13,905 Views
23 Pages

PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling

  • Lotte van Beek,
  • Éilís McClay,
  • Saleha Patel,
  • Marianne Schimpl and ,
  • Laura Spagnolo and
  • Taiana Maia de Oliveira
  • + 1 author+ 0 author

Poly (ADP-ribose) polymerases (PARP) 1-3 are well-known multi-domain enzymes, catalysing the covalent modification of proteins, DNA, and themselves. They attach mono- or poly-ADP-ribose to targets using NAD+ as a substrate. Poly-ADP-ribosylation (PAR...

(This article belongs to the Section Molecular Biology)
  • Review
  • Open Access
7 Citations
5,330 Views
21 Pages

Leveraging PARP-1/2 to Target Distant Metastasis

  • Mallory I. Frederick,
  • Djihane Abdesselam,
  • Anna Clouvel,
  • Laurent Croteau and
  • Saima Hassan

20 August 2024

Poly (ADP-Ribose) Polymerase (PARP) inhibitors have changed the outcomes and therapeutic strategy for several cancer types. As a targeted therapeutic mainly for patients with BRCA1/2 mutations, PARP inhibitors have commonly been exploited for their c...

(This article belongs to the Special Issue Cancer Biology: From Genetic Aspects to Treatment)
  • Article
  • Open Access
19 Citations
6,342 Views
25 Pages

Design, Synthesis and Molecular Modeling Study of Conjugates of ADP and Morpholino Nucleosides as A Novel Class of Inhibitors of PARP-1, PARP-2 and PARP-3

  • Yuliya V. Sherstyuk,
  • Nikita V. Ivanisenko,
  • Alexandra L. Zakharenko,
  • Maria V. Sukhanova and ,
  • Roman Y. Peshkov,
  • Ilia V. Eltsov,
  • Mikhail M. Kutuzov,
  • Tatiana A. Kurgina,
  • Ekaterina A. Belousova and
  • Tatyana V. Abramova
  • + 8 authors+ 3 authors

27 December 2019

We report on the design, synthesis and molecular modeling study of conjugates of adenosine diphosphate (ADP) and morpholino nucleosides as potential selective inhibitors of poly(ADP-ribose)polymerases-1, 2 and 3. Sixteen dinucleoside pyrophosphates c...

(This article belongs to the Special Issue Inhibition of DNA Repair Enzymes as a Valuable Pharmaceutical Approach)
  • Review
  • Open Access
122 Citations
12,459 Views
16 Pages

8 February 2020

Poly (ADP-ribose) polymerase (PARP) 1 is an essential molecule in DNA damage response by sensing DNA damage and docking DNA repair proteins on the damaged DNA site through a type of posttranslational modification, poly (ADP-Ribosyl)ation (PARylation)...

(This article belongs to the Special Issue PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer)
  • Review
  • Open Access
49 Citations
8,125 Views
26 Pages

The Multifactorial Role of PARP-1 in Tumor Microenvironment

  • Juan Manuel Martí,
  • Mónica Fernández-Cortés,
  • Santiago Serrano-Sáenz,
  • Esteban Zamudio-Martinez and ,
  • Daniel Delgado-Bellido,
  • Angel Garcia-Diaz and
  • Francisco Javier Oliver
  • + 2 authors+ 0 author

20 March 2020

Poly(ADP-ribose) polymerases (PARPs), represent a family of 17 proteins implicated in a variety of cell functions; some of them possess the enzymatic ability to synthesize and attach poly (ADP-ribose) (also known as PAR) to different protein substrat...

(This article belongs to the Special Issue PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer)
  • Article
  • Open Access
8 Citations
4,870 Views
11 Pages

Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling

  • Hannah L. Smith,
  • Elaine Willmore,
  • Asima Mukhopadhyay,
  • Yvette Drew and
  • Nicola J. Curtin

12 November 2022

Six PARP inhibitors (PARPi) are approved for cancer therapy as monotherapy agents in daily or twice-daily continuous dosing schedules to maintain the necessary continuous suppression of PARP activity. Continuous PARP inhibition is required for single...

  • Review
  • Open Access
117 Citations
14,571 Views
18 Pages

PARP inhibitors are the first clinically approved drugs that were developed based on synthetic lethality. PARP inhibitors have shown promising outcomes since their clinical applications and have recently been approved as maintenance treatment for can...

(This article belongs to the Special Issue Drug Resistance in Cancer: Molecular Mechanisms and Tackling Strategies)
  • Article
  • Open Access
7 Citations
3,368 Views
13 Pages

Increased PARP Activity and DNA Damage in NSCLC Patients: The Influence of COPD

  • Jun Tang,
  • Víctor Curull,
  • Xuejie Wang,
  • Coral Ampurdanés and ,
  • Xavier Duran,
  • Lara Pijuan,
  • Alberto Rodríguez-Fuster,
  • Rafael Aguiló,
  • José Yélamos and
  • Esther Barreiro
  • + 5 authors+ 0 author

11 November 2020

(1) Background: Lung cancer (LC) is a major leading cause of death worldwide. Poly (ADP-ribose) polymerase (PARP)-1 and PARP-2 are key players in cancer. We aimed to assess PARP-1 and PARP-2 expression and activity and DNA damage in tumors and non-tu...

(This article belongs to the Section Cancer Pathophysiology)
  • Article
  • Open Access
12 Citations
3,393 Views
12 Pages

The Prognostic Values of PARP-1 Expression in Uveal Melanoma

  • Malgorzata Gajdzis,
  • Stamatios Theocharis,
  • Jerzy Klijanienko,
  • Nathalie Cassoux and ,
  • Sophie Gardrat,
  • Piotr Donizy,
  • Radoslaw Kaczmarek and
  • Pawel Gajdzis
  • + 3 authors+ 0 author

31 January 2021

Background: Uveal melanoma is the most common primary intraocular malignancy in adults. In advanced cases, the prognosis is very poor. Thus far, no effective methods of pharmacotherapy of this cancer have been found. The aim of the study was to evalu...

(This article belongs to the Special Issue Molecular Role of PARP in Health and Disease 2020)
  • Article
  • Open Access
13 Citations
4,508 Views
25 Pages

Targeting PARP-1 and DNA Damage Response Defects in Colorectal Cancer Chemotherapy with Established and Novel PARP Inhibitors

  • Philipp Demuth,
  • Lea Thibol,
  • Anna Lemsch,
  • Felix Potlitz and ,
  • Lukas Schulig,
  • Christoph Grathwol,
  • Georg Manolikakes,
  • Dennis Schade,
  • Vassilis Roukos and
  • Jörg Fahrer
  • + 6 authors+ 1 author

10 October 2024

The DNA repair protein PARP-1 emerged as a valuable target in the treatment of tumor entities with deficiencies of BRCA1/2, such as breast cancer. More recently, the application of PARP inhibitors (PARPi) such as olaparib has been expanded to other c...

(This article belongs to the Section Cancer Therapy)
  • Review
  • Open Access
38 Citations
8,699 Views
19 Pages

PARP-1-Associated Pathological Processes: Inhibition by Natural Polyphenols

  • Natalya V. Maluchenko,
  • Alexey V. Feofanov and
  • Vasily M. Studitsky

23 October 2021

Poly (ADP-ribose) polymerase-1 (PARP-1) is a nuclear enzyme involved in processes of cell cycle regulation, DNA repair, transcription, and replication. Hyperactivity of PARP-1 induced by changes in cell homeostasis promotes development of chronic pat...

(This article belongs to the Special Issue Inhibition of DNA Repair Enzymes as a Valuable Pharmaceutical Approach)
  • Review
  • Open Access
55 Citations
9,130 Views
21 Pages

PARP Inhibitors in Breast and Ovarian Cancer

  • Samuel S. Y. Wang,
  • Yeo Ee Jie,
  • Sim Wey Cheng,
  • Goh Liuh Ling and
  • Heong Valerie Yue Ming

18 April 2023

Poly (ADP-ribose) polymerase (PARP) inhibitors are one of the most successful examples of clinical translation of targeted therapies in medical oncology, and this has been demonstrated by their effective management of BRCA1/BRCA2 mutant cancers, most...

(This article belongs to the Collection Targeting Solid Tumors)
  • Article
  • Open Access
1 Citations
1,913 Views
16 Pages

Development of Mitochondria-Targeted PARP Inhibitors

  • Pavels Dimitrijevs,
  • Marina Makrecka-Kuka and
  • Pavel Arsenyan

19 January 2026

PARP inhibitors are a clinically validated class of anticancer therapeutics that exploit synthetic lethality to target homologous recombination-deficient tumors, such as those carrying BRCA1/2 mutations. Nevertheless, the rational design of mitochond...

(This article belongs to the Section Biological Factors)
  • Review
  • Open Access
108 Citations
30,320 Views
16 Pages

PARP-1: Friend or Foe of DNA Damage and Repair in Tumorigenesis?

  • Amanda F. Swindall,
  • Jennifer A. Stanley and
  • Eddy S. Yang

26 July 2013

Oxidative stress induced by reactive oxygen species can result in DNA damage within cells and subsequently increase risk for carcinogenesis. This may be averted by repair of DNA damage through the base or nucleotide excision repair (BER/NER) pathways...

(This article belongs to the Special Issue Role of Oxidatively-Induced DNA Damage in Carcinogenesis)
  • Article
  • Open Access
3 Citations
2,004 Views
17 Pages

Background/Objectives: PARP inhibitors (PARPis) currently play frontline roles in the management of prostate, pancreatic, ovarian and breast cancers, but their roles in colorectal cancer (CRC) management have yet to be clarified. Importantly, the spe...

(This article belongs to the Special Issue Precision Oncology: Targeting Molecular Subtypes in Cancer Therapy)
  • Review
  • Open Access
22 Citations
7,133 Views
32 Pages

Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers

  • Abdullah Alhusaini,
  • Aoife Cannon,
  • Stephen G. Maher,
  • John V. Reynolds and
  • Niamh Lynam-Lennon

Gastrointestinal (GI) malignancies are a major global health burden, with high mortality rates. The identification of novel therapeutic strategies is crucial to improve treatment and survival of patients. The poly (ADP-ribose) polymerase (PARP) enzym...

(This article belongs to the Special Issue Biomarkers and New Therapeutical Strategies for Cancer Diagnosis and Treatment)
  • Review
  • Open Access
30 Citations
7,635 Views
16 Pages

The PARP Way to Epigenetic Changes

  • Simone Ummarino,
  • Clinton Hausman and
  • Annalisa Di Ruscio

20 March 2021

ADP-ribosylation, is a reversible post-translational modification implicated in major biological functions. Poly ADP-ribose polymerases (PARP) are specialized enzymes that catalyze the addition of ADP ribose units from “nicotinamide adenine dinucleot...

(This article belongs to the Section Molecular Genetics and Genomics)
  • Review
  • Open Access
131 Citations
24,870 Views
24 Pages

30 March 2019

Poly (ADP-ribose) polymerases (PARPs) play an important role in various cellular processes, such as replication, recombination, chromatin remodeling, and DNA repair. Emphasizing PARP’s role in facilitating DNA repair, the PARP pathway has been a targ...

(This article belongs to the Section Oncology)
  • Review
  • Open Access
39 Citations
4,650 Views
15 Pages

PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?

  • Amelia Barcellini,
  • Pierre Loap,
  • Kazutoshi Murata,
  • Riccardo Villa and ,
  • Youlia Kirova,
  • Noriyuki Okonogi and
  • Ester Orlandi
  • + 2 authors+ 0 author

27 October 2021

Background: Despite the large use of inhibitors of Poly-ADP ribose polymerase (PARP-I), the feasibility and safety of their combination with radiotherapy (RT) is unclear. Aim: We conducted a literature analysis with the aim to evaluate the efficacy a...

(This article belongs to the Section Molecular Cancer Biology)
  • Review
  • Open Access
75 Citations
10,119 Views
29 Pages

PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”

  • Stergios Boussios,
  • Afroditi Karathanasi,
  • Deirdre Cooke,
  • Cherie Neille and ,
  • Agne Sadauskaite,
  • Michele Moschetta,
  • Nikolaos Zakynthinakis-Kyriakou and
  • Nicholas Pavlidis
  • + 3 authors+ 0 author

Poly (ADP-ribose) polymerase (PARP) inhibitors are a novel class of therapeutic agents that target tumors with deficiencies in the homologous recombination DNA repair pathway. Genomic instability characterizes high-grade serous ovarian cancer (HGSOC)...

(This article belongs to the Special Issue Ovarian Cancer: Characteristics, Screening, Diagnosis and Treatment)
  • Review
  • Open Access
27 Citations
11,428 Views
15 Pages

PARP Inhibitors in Melanoma—An Expanding Therapeutic Option?

  • Wei Yen Chan,
  • Lauren J. Brown,
  • Lee Reid and
  • Anthony M. Joshua

8 September 2021

Immunotherapy has transformed the treatment landscape of melanoma; however, despite improvements in patient outcomes, monotherapy can often lead to resistance and tumour escape. Therefore, there is a need for new therapies, combination strategies and...

(This article belongs to the Special Issue Systemic Therapies in Melanoma)
  • Article
  • Open Access
613 Views
11 Pages

PET Imaging of New Target PARP in Prostate Cancer

  • Zhao Yang,
  • Wei Wang,
  • Xuanyi Dai,
  • Liya Wei and ,
  • Yanli Li,
  • Wenfeng Gou and
  • Feifei Xu
  • + 2 authors+ 0 author

30 June 2026

Background/Objectives: Poly (ADP-ribose) polymerase (PARP), particularly PARP-1, is overexpressed in prostate cancer and linked to poor prognosis. PARP inhibitors show efficacy in homologous recombination deficiency (HRD)-positive tumors, but 30&ndas...

  • Review
  • Open Access
21 Citations
6,783 Views
18 Pages

5 June 2022

PARP1 enzyme plays an important role in DNA damage recognition and signalling. PARP inhibitors are approved in breast, ovarian, pancreatic, and prostate cancers harbouring a pathogenic variant in BRCA1 or BRCA2, where PARP1 inhibition results mainly...

(This article belongs to the Special Issue A Deeper Dive into Signaling Pathways in Cancers)
  • Feature Paper
  • Review
  • Open Access
68 Citations
10,360 Views
25 Pages

25 July 2020

The use of PARP inhibitors (PARPi) is growing widely as FDA approvals have shifted its use from the recurrence setting to the frontline setting. In parallel, the population developing PARPi resistance is increasing. Here we review the role of PARP, D...

(This article belongs to the Special Issue Preclinical and Clinical Advances in Ovarian Cancer)
  • Review
  • Open Access
78 Citations
10,124 Views
20 Pages

Role of Akt Activation in PARP Inhibitor Resistance in Cancer

  • Ferenc Gallyas,
  • Balazs Sumegi and
  • Csaba Szabo

25 February 2020

Poly(ADP-ribose) polymerase (PARP) inhibitors have recently been introduced in the therapy of several types of cancers not responding to conventional treatments. However, de novo and acquired PARP inhibitor resistance is a significant limiting factor...

(This article belongs to the Special Issue PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer)
  • Article
  • Open Access
7 Citations
5,049 Views
12 Pages

Effect of Notch and PARP Pathways’ Inhibition in Leukemic Cells

  • Luka Horvat,
  • Mariastefania Antica and
  • Maja Matulić

14 June 2018

Differentiation of blood cells is one of the most complex processes in the body. It is regulated by the action of transcription factors in time and space which creates a specific signaling network. In the hematopoietic signaling system, Notch is one...

  • Article
  • Open Access
25 Citations
5,484 Views
13 Pages

Radiosynthesis and Evaluation of Talazoparib and Its Derivatives as PARP-1-Targeting Agents

  • Dong Zhou,
  • Huaping Chen,
  • Cedric Mpoy,
  • Sadia Afrin and ,
  • Buck E. Rogers,
  • Joel R. Garbow,
  • John A. Katzenellenbogen and
  • Jinbin Xu
  • + 3 authors+ 0 author

Poly (ADP-ribose) polymerase-1 (PARP-1) is a critical enzyme in the DNA repair process and the target of several FDA-approved inhibitors. Several of these inhibitors have been radiolabeled for non-invasive imaging of PARP-1 expression or targeted rad...

(This article belongs to the Section Drug Discovery and Development)
  • Review
  • Open Access
24 Citations
8,289 Views
18 Pages

3 October 2023

Poly(ADP-ribose) polymerase (PARP) enzymes have been shown to be essential for DNA repair pathways, including homologous recombination repair (HRR). Cancers with HRR defects (e.g., BRCA1 and BRCA2 mutations) are targets for PARP inhibitors (PARPis) b...

(This article belongs to the Section Molecular Medicine)
  • Review
  • Open Access
11 Citations
5,081 Views
25 Pages

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer

  • Andrisha-Jade Inderjeeth,
  • Monique Topp,
  • Elaine Sanij,
  • Elena Castro and
  • Shahneen Sandhu

30 November 2022

Approximately a quarter of men with metastatic castrate resistant prostate cancer (mCRPC) have alterations in homologous recombination repair (HRR). These patients exhibit enhanced sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors. Leverag...

(This article belongs to the Special Issue Clinical Use of PARP Inhibitors in Cancer – From Bench to Bedside and Back Again)
  • Review
  • Open Access
11 Citations
4,642 Views
16 Pages

Epigenetic Insights on PARP-1 Activity in Cancer Therapy

  • Giulia Pinton,
  • Sara Boumya,
  • Maria Rosa Ciriolo and
  • Fabio Ciccarone

20 December 2022

The regulation of chromatin state and histone protein eviction have been proven essential during transcription and DNA repair. Poly(ADP-ribose) (PAR) polymerase 1 (PARP-1) and poly(ADP-ribosyl)ation (PARylation) are crucial mediators of these process...

(This article belongs to the Special Issue Clinical Use of PARP Inhibitors in Cancer – From Bench to Bedside and Back Again)
  • Review
  • Open Access
25 Citations
7,178 Views
22 Pages

Existing Evidence for the Repurposing of PARP-1 Inhibitors in Rare Demyelinating Diseases

  • Marianna Mekhaeil,
  • Kumlesh Kumar Dev and
  • Melissa Jane Conroy

29 January 2022

Over the past decade, Poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors have arisen as a novel and promising targeted therapy for breast cancer gene (BRCA)-mutated ovarian and breast cancer patients. Therapies targeting the enzyme, PARP-1, have sinc...

(This article belongs to the Section Cancer Therapy)
  • Review
  • Open Access
41 Citations
10,500 Views
34 Pages

PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword

  • Clifford M. Csizmar,
  • Antoine N. Saliba,
  • Elizabeth M. Swisher and
  • Scott H. Kaufmann

20 December 2021

Despite recent discoveries and therapeutic advances in aggressive myeloid neoplasms, there remains a pressing need for improved therapies. For instance, in acute myeloid leukemia (AML), while most patients achieve a complete remission with convention...

(This article belongs to the Special Issue Clinical Use of PARP Inhibitors in Cancer – From Bench to Bedside and Back Again)
  • Review
  • Open Access
87 Citations
13,744 Views
15 Pages

PARP Inhibitors Resistance: Mechanisms and Perspectives

  • Elena Giudice,
  • Marica Gentile,
  • Vanda Salutari,
  • Caterina Ricci and ,
  • Lucia Musacchio,
  • Maria Vittoria Carbone,
  • Viola Ghizzoni,
  • Floriana Camarda,
  • Francesca Tronconi and
  • Domenica Lorusso
  • + 8 authors+ 3 authors

10 March 2022

PolyADP-ribose polymerase (PARP) inhibitors (PARPis) represent the first clinically approved drugs able to provoke “synthetic lethality” in patients with homologous recombination-deficient (HRD) tumors. Four PARPis have just received appr...

(This article belongs to the Special Issue Clinical Use of PARP Inhibitors in Cancer – From Bench to Bedside and Back Again)
  • Article
  • Open Access
12 Citations
4,845 Views
13 Pages

PARP-1 Expression and BRCA1 Mutations in Breast Cancer Patients’ CTCs

  • Thodoris Sklias,
  • Vasileios Vardas,
  • Evangelia Pantazaka,
  • Athina Christopoulou and ,
  • Vassilis Georgoulias,
  • Athanasios Kotsakis,
  • Yiannis Vasilopoulos and
  • Galatea Kallergi
  • + 3 authors+ 0 author

29 March 2022

BRCA1 and PARP are involved in DNA damage repair pathways. BRCA1 mutations have been linked to higher likelihood of triple negative breast cancer (TNBC). The aim of the study was to determine PARP-1 expression and BRCA1 mutations in circulating tumor...

(This article belongs to the Special Issue Promising Biomarkers in Liquid Biopsy of Cancer)
  • Article
  • Open Access
4 Citations
2,853 Views
13 Pages

An Array SPRi Biosensor for the Determination on PARP-1 in Blood Plasma

  • Zuzanna Zielinska,
  • Lukasz Oldak,
  • Joanna Kacperczyk-Bartnik,
  • Ewa Koc-Żórawska and ,
  • Marcin Żórawski,
  • Piotr Laudanski and
  • Ewa Gorodkiewicz
  • + 2 authors+ 0 author

A biosensor was developed for the quantification of poly(ADP-ribose) polymerase-1 (PARP-1) in body fluids. An antibody specific for PARP-1 was placed on a chip with cysteamine (linker) and a gold layer. This biosensor has a linear response range (10&...

(This article belongs to the Section Biomedical Engineering and Materials)
  • Review
  • Open Access
20 Citations
7,687 Views
22 Pages

Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy

  • Naveen Singh,
  • S. Louise Pay,
  • Snehal B. Bhandare,
  • Udhaya Arimpur and
  • Edward A. Motea

14 April 2020

Poly-(ADP-ribose) polymerase 1 (PARP1) is commonly known for its vital role in DNA damage response and repair. However, its enzymatic activity has been linked to a plethora of physiological and pathophysiological transactions ranging from cellular pr...

(This article belongs to the Special Issue PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer)
  • Review
  • Open Access
45 Citations
17,121 Views
14 Pages

22 August 2017

Poly-(ADP-ribose) polymerase (PARP) inhibitors act through synthetic lethality in cells with defects in homologous recombination (HR) DNA repair caused by molecular aberrations such as BRCA mutations, and is approved for treatment in ovarian cancer,...

(This article belongs to the Special Issue DNA Repair Pathways in Cancer)
  • Article
  • Open Access
13 Citations
2,697 Views
15 Pages

15 October 2024

Pyruvate serves as a key metabolite in energy production and as an anti-oxidant. In our previous study, exogenous pyruvate starvation under high-glucose conditions induced IMS32 Schwann cell death because of the reduced glycolysis–tricarboxylic...

(This article belongs to the Special Issue Peripheral Neuropathies: Molecular Research and Novel Therapy)
  • Review
  • Open Access
12 Citations
3,872 Views
19 Pages

Advancements and Obstacles of PARP Inhibitors in Gastric Cancer

  • Hongjie Chen,
  • Yangchan Hu,
  • Zirui Zhuang,
  • Dingyi Wang and ,
  • Zu Ye,
  • Ji Jing and
  • Xiangdong Cheng
  • + 2 authors+ 0 author

24 October 2023

Gastric cancer (GC) is a common and aggressive cancer of the digestive system, exhibiting high aggressiveness and significant heterogeneity. Despite advancements in improving survival rates over the past few decades, GC continues to carry a worrisome...

(This article belongs to the Special Issue Advances in Cancer Therapeutics)
  • Review
  • Open Access
24 Citations
7,618 Views
14 Pages

BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme

  • Mary-Ann Xavier,
  • Fernando Rezende,
  • Ricardo Titze-de-Almeida and
  • Bart Cornelissen

11 August 2021

Glioblastoma multiforme (GBM) is the most common primary brain cancer. GBMs commonly acquire resistance to standard-of-care therapies. Among the novel means to sensitize GBM to DNA-damaging therapies, a promising strategy is to combine them with inhi...

(This article belongs to the Special Issue New Advances in Molecular Oncology)
  • Review
  • Open Access
12 Citations
7,258 Views
27 Pages

Role of PARP Inhibitors: A New Hope for Breast Cancer Therapy

  • Kamalendu De,
  • Malabendu Jana,
  • Bhabadeb Chowdhury,
  • Gloria M. Calaf and
  • Debasish Roy

Tumors formed by the unchecked growth of breast cells are known as breast cancer. The second most frequent cancer in the world is breast cancer. It is the most common cancer among females. In 2022, 2,296,840 women were diagnosed with breast cancer. T...

(This article belongs to the Special Issue Hormone Receptors and Signaling in Breast Cancer)
  • Review
  • Open Access
58 Citations
12,054 Views
19 Pages

PARP Inhibitors in Prostate Cancer–the Preclinical Rationale and Current Clinical Development

  • Verneri Virtanen,
  • Kreetta Paunu,
  • Johanna K. Ahlskog,
  • Reka Varnai and ,
  • Csilla Sipeky and
  • Maria Sundvall
  • + 1 author+ 0 author

26 July 2019

Prostate cancer is globally the second most commonly diagnosed cancer type in men. Recent studies suggest that mutations in DNA repair genes are associated with aggressive forms of prostate cancer and castration resistance. Prostate cancer with DNA r...

(This article belongs to the Special Issue Prostate Cancer Genetics and the Emergence of Targeted Therapies Based on Molecular Profiling)
  • Article
  • Open Access
11 Citations
3,597 Views
30 Pages

15 September 2022

Human cytomegalovirus (HCMV) is a ubiquitous pathogen that threats the majority of the world’s population. Poly (ADP-ribose) polymerase 1 (PARP-1) and protein poly (ADP-ribosyl)ation (PARylation) regulates manifold cellular functions. The role...

(This article belongs to the Special Issue Herpesvirus Manipulation of Cellular Processes 2.0)
  • Article
  • Open Access
23 Citations
5,604 Views
13 Pages

PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation

  • Stephanie Jonuscheit,
  • Tina Jost,
  • Fritzi Gajdošová,
  • Maximilian Wrobel and ,
  • Markus Hecht,
  • Rainer Fietkau and
  • Luitpold Distel
  • + 2 authors+ 0 author

31 May 2021

(1) Background: Niraparib and Talazoparib are poly (ADP-ribose) polymerase (PARP) 1/2 inhibitors. It is assumed that combining PARP inhibitors with radiotherapy could be beneficial for cancer treatment. In this study, melanoma cells were treated with...

(This article belongs to the Special Issue Mechanisms of DNA Damage, Repair and Mutagenesis)
  • Article
  • Open Access
40 Citations
5,509 Views
16 Pages

PARP Inhibition Increases the Response to Chemotherapy in Uveal Melanoma

  • Leanne de Koning,
  • Didier Decaudin,
  • Rania El Botty,
  • André Nicolas and ,
  • Guillaume Carita,
  • Mathieu Schuller,
  • Bérengère Ouine,
  • Aurélie Cartier,
  • Adnan Naguez and
  • Fariba Némati
  • + 16 authors+ 11 authors

29 May 2019

Uveal melanoma (UM) remains without effective therapy at the metastatic stage, which is associated with BAP-1 (BRCA1 associated protein) mutations. However, no data on DNA repair capacities in UM are available. Here, we use UM patient-derived xenogra...

(This article belongs to the Special Issue Uveal Melanoma)
  • Article
  • Open Access
5 Citations
2,902 Views
15 Pages

Modulation of PARP-1 Activity in a Broad Time Window Attenuates Memorizing Fear

  • Einat Elharrar,
  • Yahav Dikshtein,
  • Sapir Meninger-Mordechay,
  • Yehuda Lichtenstein and
  • Gal Yadid

The amygdala plays a critical role in the acquisition and consolidation of fear-related memories. Recent studies have demonstrated that ADP-ribosylation of histones, accelerated by PARPs, affects the chromatin structure and the binding of chromatin r...

(This article belongs to the Special Issue Psychoneuropharmacology)
  • Article
  • Open Access
1,004 Views
15 Pages

Inactivation of PRMT5 by PARP Inhibitors Confers High Susceptibility in MTAP-Deficient Cancers

  • Qi Liu,
  • Yuling Sheng,
  • Folan Lin,
  • Haoyuan Tan and ,
  • Yanyun Chang,
  • Xiaopeng Lu,
  • Hao Chen and
  • Changzheng Du
  • + 3 authors+ 0 author

22 April 2026

Background: Methylthioadenosine phosphorylase (MTAP) deficiency caused by homozygous deletion is prevalent in solid tumors and contributes to malignant progression, thereby rendering cancer cells vulnerable to dysfunction of protein arginine methyltr...

(This article belongs to the Section Molecular Cancer Biology)
  • Article
  • Open Access
11 Citations
7,921 Views
14 Pages

Design, Synthesis, and In Vitro Evaluation of the Photoactivatable Prodrug of the PARP Inhibitor Talazoparib

  • Jiaguo Li,
  • Dian Xiao,
  • Lianqi Liu,
  • Fei Xie and ,
  • Wei Li,
  • Wei Sun,
  • Xiaohong Yang and
  • Xinbo Zhou
  • + 3 authors+ 0 author

18 January 2020

In this article, we report the design, synthesis, photodynamic properties, and in vitro evaluation of photoactivatable prodrug for the poly (ADP-ribose) polymerase 1 (PARP-1) inhibitor Talazoparib. In order to yield a photoactivatable, inactive prodr...

(This article belongs to the Special Issue Anticancer Agents: Design, Synthesis and Evaluation)

of 47